Equity · Healthcare
ALXO
NASDAQALX Oncology Holdings (ALXO)
The line runs 2 USD on 12 August through 1.28 USD on 9 November, on a scale from 0.5 to 2.5. Days the market did not trade hold the previous close, flat.
- Market cap
- 176.3M USD
- EPS, diluted, year to Dec 2025
- −1.90 USD
- 52-week range
- 0.8973 USD – 2.60 USD
- Avg volume
- 114.7K
as of Nov 9, 2026
Have ALX Oncology Holdings (ALXO) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, ALX Oncology Holdings insiders reported 2 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 2 Feb 2026.
Form 4, 90 days to 10 Nov 2026, newest reported trade 17 Aug 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 17 Aug 2026 | Lettmann JasonCHIEF EXECUTIVE OFFICER | Sell | 2,230 | 4K USD |
| 17 Aug 2026 | Wong ShellySVP, FINANCE AND CAO | Sell | 573 | 1K USD |
| Sold | 2 open-market sales | 2,803 | $5K |
Which funds hold ALX Oncology Holdings (ALXO)?
4 of the 45 institutional funds we track reported a ALX Oncology Holdings position for the quarter ended 30 Jun 2026 — a combined 15.3M USD; the latest of those filings landed 14 Aug 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Marshall Wace | Held (±25%) | 3,071,496 | 6.4M USD | −18.3% |
| Two Sigma Investments | Added | 2,178,176 | 4.5M USD | +37.2% |
| Millennium Management | Held (±25%) | 1,543,594 | 3.2M USD | −22.4% |
| Renaissance Technologies | Held (±25%) | 603,797 | 1.2M USD | −17.6% |
| Point72 Asset Management | Exited |
What has been filed or recorded for ALX Oncology Holdings (ALXO)?
The filings we hold for ALX Oncology Holdings, newest first: 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 30 Jun 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.13 USD | |
| 30 Jun 2026 | Financials | Total assets | 160.8M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 136.2M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.17 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.90 USD | |
| 31 Dec 2025 | Financials | Net income | −101.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −1.90 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.41 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.49 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.58 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −2.58 USD | |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −0.58 USD |
What do people ask about ALX Oncology Holdings (ALXO)?
What did ALX Oncology Holdings shares close at?1.28
ALX Oncology Holdings closed at 1.28 USD on 9 Nov 2026, up 10.39% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is ALX Oncology Holdings’ market cap?176.3M
ALX Oncology Holdings is worth 176.3M USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
Have ALX Oncology Holdings insiders bought or sold shares recently?2 sales
In the 90 days to 10 Nov 2026, ALX Oncology Holdings insiders reported 2 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 2 Feb 2026. See Insiders
Which funds own ALX Oncology Holdings?4 of 45
4 of the 45 funds we track reported a ALX Oncology Holdings position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Marshall Wace, Two Sigma Investments and Millennium Management. See Funds
When did ALX Oncology Holdings last report earnings?−0.13
ALX Oncology Holdings last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.13 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings